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Abstract. Determining the expression of genes in response to 
different classes of chemotherapeutic drugs may allow for a 
better understanding as to which may be used effectively in 
combination. In the present study, the human colorectal cancer 
cell line HCT116 was cultured with equi‑active concentrations 
of a series of anti‑cancer agents. Gene expression profiles 
were then measured by whole‑genome microarray. Although 
each drug induced a unique signature of gene expression in 
tumour cells, there were marked similarities between certain 
drugs, even in those from different classes. For example, the 
antimalarial agent artesunate and the platinum‑containing 
alkylating agent, oxaliplatin, produced a very similar mRNA 
expression pattern in HCT116 cells with ~14,000 genes being 
affected by the two drugs in the same way. Furthermore, the 
overall correlation of gene responses between two agents 
could predict whether their use in combination would lead to 
a greater or lesser effect on cell number, determined experi‑
mentally, than predicted by single agent experiments. The 
results indicated that even when working through different 
mechanisms, combining drugs that initiate a similar transcrip‑
tional response may constitute the best option for determining 
drug‑combination strategies for the treatment of cancer.
Introduction
Combining chemotherapy drugs to treat cancer is a common 
approach used in an attempt to enhance treatment strategies, 
and to counteract the development of resistant cancer cells. 
For example, utilising drugs such as folinic acid, 5‑fluoro‑
uracil (5‑FU) and oxaliplatin (OXP) in combination that makes 
up the FOLFOX chemotherapy regimen has brought good effi‑
cacy in approaches to treat some colon cancers (1). Similarly, 
in breast cancer, a combination of cyclophosphamide, 5‑FU, 
epirubicin or methotrexate are often used together. However, 
the use of particular chemotherapy drugs in certain cancer 
are often selected based upon historical success of the single 
agent, and rationales for chemotherapy combinations are often 
nebulous and ill‑defined (2).
Generally, drugs from different chemotherapeutic classes 
are partnered with one another because they may exhibit 
different mechanisms of action, have minimally overlap‑
ping spectra of toxicity and target discrete phases of the cell 
cycle (3). This is thought to increase efficacy of the treatments 
and reduces the probability of the tumour acquiring resistance. 
However, despite cancer treatment algorithms and a drive 
towards personalised medicine combination strategies can still 
lack a rigorous scientific rationale, and few have been assessed 
to establish optimal dose, schedule and delivery. Instead, 
a ‘hit and hope’ approach can be adopted, which does not 
necessarily lead to the most effective treatment for individual 
patients. Indeed, the vagaries of combination regimen when 
considered with the intrinsic diversity of tumours and sensi‑
tivities to differing treatments, means a more rational plan for 
the combination of chemotherapies is needed.
Identifying the drug combinations suitable for certain 
diseases requires a more careful understanding of the mecha‑
nisms of action for each drug involved in a regimen. It is only 
by understanding profoundly the effects of each that the best 
partners can be identified. However, and more bafflingly, it is 
also not enough to understand the effect of a drug as these 
typically are assessed in single‑agent setting. Once drugs 
are combined, the profile and complexity of the interactions 
can alter the expected outcome. For example the use of 
monoclonal antibodies to neutralise cytotoxic T‑lymphocyte 
associated antigen 4 (CTLA‑4) can induce anticancer activity; 
however, this can cause a compensatory increase in the 
programmed‑death 1 (PD‑1) receptor, which can ultimately 
suppress the overall anticancer action. For this reason, the 
sequential use of CTLA‑4 and PD‑1 antagonists could over‑
come the resistance by using the former drug alone (4).
In addition to simply killing, chemotherapeutic drugs can 
interfere with intracellular processes rendering cells more 
susceptible to other treatments, be they chemo‑, immuno‑ or 
radiotherapies (5‑7). The effects on cell signalling can occur 
even when the chemotherapy is used at doses that do not have 
a great effect on cell number (8,9). Attempts are being under‑
taken to assess the impact of the genetic landscape on drug 
efficacy (10). Knowledge of the signalling modulation and 
transcriptional changes instigated by each chemotherapy will 
The efficacy of chemotherapeutic drug combinations may be 
predicted by concordance of gene response to the single agents
ANDREW M. GRAVETT,  JAYNE L. DENNIS,  ANGUS G. DALGLEISH,  JOHN COPIER  and  WAI M. LIU
Institute for Infection and Immunity, Department of Oncology, St. George's, University of London, London SW17 0RE, UK
Received September 19, 2019;  Accepted July 10, 2020
DOI: 10.3892/ol.2020.12184
Correspondence to: Dr Wai M. Liu, Institute for Infection and 
Immunity, Department of Oncology, St. George's, University of 
London, Cranmer Terrace, London SW17 0RE, UK
E‑mail: wliu@sgul.ac.uk
Key words: chemotherapeutics, microarray, combinations, cancer
GRAVETT et al:  EFFICACY OF CHEMOTHERAPEUTIC DRUG COMBINATIONS2
allow for a more holistic approach to combination selection. 
Current thinking goes even further than this with ‘precision’ 
chemotherapy approaches being investigated, where even 
knowledge of the tumour's transcriptional background being 
taken into consideration when designing treatment regi‑
mens (8,11,12).
Chemotherapy drugs can be divided into a number 
of different classes, including: Alkylating agents, such as 
oxaliplatin (OXP), that work by covalently cross‑linking 
deoxyribonucleic acid (DNA) strands via their alkyl group; 
antimetabolites, such as gemcitabine (GEM), that block 
DNA replication; mitosis dysregulators, such as docetaxel 
(DOC), that stop cancer cells completing mitosis by inter‑
fering with proper microtubule function and others, such as 
the iMiDs, which target cereblon and have anti‑proliferative, 
anti‑inflammatory and anti‑angiogenic properties (13,14), and 
the artemisinins, which are anti‑malarial drugs that have been 
reported to not only retard tumour cell growth in vitro but also 
be excellent combinatorial partners for other drugs (15,16). 
Artemisinins initiate apoptosis in tumour cells through 
iron‑catalyzed lysosomal activation and reactive oxygen 
species production (17,18).
In this study the colorectal tumour cell line, HCT116, was 
treated with equi‑active concentrations on OXP, GEM, DOC, 
the iMiD lenalidomide (LEN) and a semi‑synthetic derivative 
of artemisinin, artesunate (ARS). A brief summary of each 
drug is shown in Table I. The effect of each drug on gene tran‑
scription was then measured by microarray and this was used 
to predict whether particular drugs would be exhibit syner‑
gistic or antagonistic characteristics when combined with one 
another to inhibit tumour cell growth.
Materials and methods
Tumour cell lines. The human colorectal cancer cell line 
HCT116 (Public Health England) was grown in complete 
DMEM medium (Sigma‑Aldrich, Dorset, UK) supplemented 
with 10% foetal bovine serum (FBS) (Invitrogen, Paisley, 
UK), 2 mM L‑glutamine and 1% penicillin/streptomycin 
(both Sigma). Authentication of this cell line was performed 
by the service provider using the AmpFISTR Identifier Plus 
PCR amplification kit looking for the presence of <10 known 
loci for each cell line. Cells were incubated in a humidified 
atmosphere with 5% CO2 in air at 37˚C. When approximately 
75% confluency was reached, cells were harvested with trypsin 
(Sigma‑Aldrich) prior to washing and reseeding at a lower cell 
density. Only cells with a passage number <15 were used in 
experiments.
Drugs. GEM, OXP, CPM, camptothecin (all from 
Sigma‑Aldrich), artesunate (ARS) (St. George's Hospital 
Pharmacy) and LEN (Celgene Corp.) were reconstituted in 
phosphate‑buffered saline (PBS) (Sigma), or in the case of 
LEN and DOC, dimethyl sulfoxide (DMSO) (Sigma‑Aldrich), 
to create a top stock solution of 100 mM, which and stored 
at ‑80˚C long‑term and ‑20˚C short‑term (up to one month). 
Where necessary, all drugs were diluted in PBS. When adding 
drug to cell culture, volume and DMSO concentration were 
maintained for each condition, DMSO concentration was 
always <0.01%. Cells were allowed to adhere overnight before 
drugs were added at equi‑active concentrations based on our 
previous work (5,15). Final concentrations were: ARS (1 µM), 
DOC (10 nM), GEM (100 nM), LEN (1 µM), NAL (1 µM) and 
OXP (500 nM). Tumour cells were then cultured for a further 
48 h, at which time, cell numbers were assessed by MTT. 
Additionally, the effect of treatment on the gene expression 
was assessed by isolating RNA from cells cultured with the 
drugs for 4 h. These samples were processed for subsequent 
microarray analyses.
Illumina microarrays. RNA was isolated from control or 
HCT116 cells treated with ARS, DOC, GEM, LEN, NAL 
or OXP using the Qiagen mini‑kit according to the instruc‑
tions of the manufacturer. The concentration and quality 
of the resultant RNA was determined using NanoDrop and 
2100 Bioanalyzer (Agilent Technologies). The RNA was 
found to be extremely pure with OD260/280 ratios measured 
by nanodrop >1.90 and electropherograms confirmed intact 
RNA. Microarrays were performed by Dr Jayne Dennis at 
the St. George's, University of London Biomics Centre. 
Biotinylated cRNA was generated from 100 ng total RNA 
using the Illumina TotalPrep RNA Amplification Kit (Applied 
Biosystems; Thermo Fisher Scientific, Inc.) according to 
manufacturer's instructions. Equal amounts (750 ng) of 
cRNA were hybridised to the Illumina human HT12‑v3 
arrays for 18 h. These arrays consisted of more than 48,000 
probes covering RefSeq and UniGene annotated genes, 
and acquisitions were subsequently processed according to 
manufacturer's instructions before scanning on an Illumina 
BeadArray Reader. The image data were processed using 
default values in GenomeStudio v2009.1 with imputation of 
missing data, before loading onto GeneSpring v9.0 for data 
normalisation and filtering. Gene‑ontology (GO)‑enrichment 
analysis was also performed (19‑21). Gene activity values 
represent the mean of three separate experiments that were 
used as scientific replicates i.e. each experiment represented 
a single well on the microarray chip.
Methylthiazoletetrazolium (MTT) assays. To study the 
effect of drugs on the number of viable cells, cells growing 
exponentially were added to 96‑well plates at a density of 
3x104 cells/ml in 180 µl complete medium. After the cells 
had been allowed to adhere overnight, 20 µl of drug stock 
solutions were added to the wells to the appropriate final 
concentration. The number of viable cells was measured 
at 48 h using a standard MTT‑based assay without modifica‑
tions. Briefly, MTT (Sigma‑Aldrich) was added to each well 
to give a working concentration of 0.4 mg/ml, and plates 
returned to 37˚C for a further h. After this time, the medium 
was aspirated off, 200 µl DMSO added to each well and plates 
agitated gently for one minute before measuring optical 
density at 550 nm using a microplate reader (Dynex‑MRX II; 
Dynex Technologies Ltd.). Each sample was run in triplicate 
and experiment was completed three times.
Statistical analysis of correlation and gene ontology analysis. 
R2 values and Spearman's Rank Correlation Coefficients were 
obtained using Microsoft Excel 2019 v1808. Gene ontology 
(GO) analysis was performed using Gene Ontology Resource 
(http://geneontology.org/).
ONCOLOGY LETTERS  20:  321,  2020 3
Results
Each drug produced a specific signature of gene activa-
tion/inhibition in HCT116 cells. HCT116 cells treated with 
equi‑active concentrations of various drugs were assessed by 
microarray. The 25 most upregulated and 25 most downregu‑
lated genes were then listed for each treatment and the change 
in those genes in response to the other drugs was then evalu‑
ated (Fig. 1). Genes with a ≥3‑fold mRNA expression increase 
after treatment are shown in green, graded to white which 
indicates no change. Genes with a ≥3‑fold mRNA decrease 
after treatment are shown in red, again graded to white which 
indicates no change. The left‑hand panel shows the genes 
that were most strongly upregulated or downregulated in 
response to GEM and how those same genes were affected by 
the other treatments. OXP and CAM appeared to upregulate 
some of the same genes as GEM, as shown by the number of 
genes highlighted in green in the second lane (O) and sixth 
lane (C) in the top half of the panel. Genes that were strongly 
upregulated by GEM were not greatly affected by DOC, LEN 
and ARS, indicated by the pale grading of the genes in these 
lanes. Conversely, genes that were downregulated by GEM, 
shown in the bottom half of the left panel and coloured red 
were upregulated by DOC and consequently appear green. 
This discordance between GEM and DOC holds true when 
the analysis is performed on the genes most affected by DOC 
treatment (3rd panel on top row), where many of the genes that 
are most upregulated by treatment with DOC are downregu‑
lated by GEM. By analysing the data in this way it is possible 
to infer which treatments are more similar or more different 
with regards to their effect on gene transcription. The drugs 
DOC, LEN and ART seemed to produce a similar pattern of 
gene changes in HCT116 cells, as did GEM, CAM and OXP. 
The gene changes induced by naltrexone treatment did not 
appear to share many similarities with the other treatments.
The pattern of affected genes was similar between drugs with 
disparate mechanisms. To understand whether similarities in 
genetic profiles of different drugs could determine the combi‑
nation benefit, HCT116 cells were cultured with equi‑active 
concentrations of each of the drug, and RNA extracted after 
4 h for gene microarray analyses. Changes in gene expression 
relative to the untreated control were then sorted for each drug, 
and the similarities in their patterns determined. Gene expres‑
sion was termed ‘altered by treatment’ if the expression had 
changed ±25% or more from control and otherwise regarded 
as unchanged. Gene lists were then judged against each other 
to determine how changes in the expression of the individual 
genes compared and contrasted following a particular treat‑
ment.
The effect of the treatment on each gene in the microarray 
was assessed and changes that were in agreement in terms of 
the direction of change, irrespective of magnitude, were defined 
as being concordant. For example, expression of the gene, 
aurora kinase A, was increased following treatment with GEM 
and CAM, decreased after DOC and NAL and unchanged in 
response to OXP, LEN and ART. Consequently, this gene 
was called concordant between GEM and CAM, discordant 
between GEM and DOC or NAL and mixed between GEM 
and the other treatment pairs. By using this method of analysis, 
pairs of drugs could be assessed for the extent of the concor‑
dance in genes. Results showed that ART and LEN had the 
greatest number of genes (14,186) that were altered in a similar 
manner following treatment (Fig. 2A). Conversely, CAM and 
NAL had the fewest number of concordant genes (7343) and 
the most mixed (Fig. 2B) and discordant genes (Fig. 2C). 
As a larger proportion of concordant genes could be those 
unchanged after treatment, these were excluded in subsequent 
analysis where the percentage of concordant, discordant or 
mixed genes for each treatment pair is shown (Fig. 2D).
There were good correlations in the changes to certain gene 
families following treatment. The effect of each of the drugs on 
genes named on the Qiagen ‘apoptosis gene list’ was assessed. 
The changes were then ranked in order of the magnitude of 
change for each gene, and these ranked‑lists compared with 
each other. For example, the r2‑value was 0.664 for lenalido‑
mide vs. docetaxel, which suggested a good positive correlation 
in apoptosis‑genes affected by the drugs (Fig. 3A). Conversely, 
there was no correlation between the apoptosis‑related genes 
affected by naltrexone and oxaliplatin (r2=‑0.022; Fig. 3B). A 
similar analysis using lists of genes involved in the cell cycle 
showed similarities and differences between the drugs; with 
lenalidomide and docetaxel being the drug pair displaying 
the highest correlation (r2=0.610; Fig. 3C) and naltrexone and 
lenalidomide displaying the least correlation (r2=0.014; Fig. 3D). 
In addition to any effects on apoptosis or cell cycle genes, gene 
ontology enrichment analysis revealed which cellular processes 
were impacted by each treatment (Table II). Genes related to 
the DNA damage response, cellular stress, apoptosis and cell 
cycle were overrepresented in the 100 most affected genes after 
culturing cells with the DNA damaging chemotherapies such 
as CAM, GEM and OXP. Each of these drugs seemed to be 
involved in the activation or repression of numerous cellular 
processes. In contrast, DOC showed only enrichment in ‘cell 
division’ and LEN in no processes at all. That is not to say that 
LEN did not affect any cellular process, just that the drug did 
not affect any particular process disproportionately.
Combinational value correlated with gene concordance. 
MTT analysis was performed on HCT116 cells that had been 
cultured with the chemotherapeutic drugs either as single 
agents or as selected combinations for 48 h, a representative 
example of data is shown in Fig. 4A. The difference between 
the expected effect on cell number by combining two drugs 
(generated by adding together of the results of the effect on cell 
Table I. List of drugs used for microarray experiments.
Name Class  Target
Artesunate Anti‑malarial Lysosomal Iron
Camptothecin Topoisomerase Inhibitor Topoisomerase
Docetaxel Mitosis inhibitor Microtubules
Gemcitabine Antimetabolite DNA
Lenalidomide Immune modulatory Cereblon
Naltrexone Other Not known
Oxaliplatin Alkylating agent DNA
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number of each single agent) was then compared to the actual 
result of combining the two drugs together. Using this analysis 
it was possible to find drug combinations that performed better 
or worse than the predicted effect by single‑agent analysis 
(Fig. 4B). The combination of artesunate and lenalidomide 
performed the best, exceeding the predicted effect on cell 
number. The combinations of artesunate and docetaxel and 
artesunate and oxaliplatin also performed better than 
expected. The combination of lenalidomide and camptothecin 
performed worst and had a less than predicted effected on cell 
Figure 1. Heat maps demonstrating the genes most affected by each drug and how this compared with other treatments. The 25 most upregulated and 25 most 
downregulated genes in response to each drug in microarray experiments were listed and then presented in terms of their response to other drugs. Colour 
grading indicates the magnitude of change from untreated controls: Green indicates ≥3‑fold increase, white indicates no change, red indicates ≥3‑fold decrease. 
Data taken from microarray experiments were repeated three times and used as a single replicate.
Figure 2. Data form microarray experiments was used to compare drug pairs for concordance of gene responses. The cut‑off used for a change in gene 
expression was a 20% increase or decrease from untreated controls. (A) The number of concordant genes for each drug pair is presented. Genes were termed 
concordant if they responded to both drugs in the same way. (B) The number of ‘mixed’ genes is presented. Mixed genes were defined as those which were 
altered in response to one drug but unchanged in response to the other. (C) The number of genes that were discordant between drug pairs is demonstrated. For 
example, increased by one drug and decreased by the other. (D) presents the percentage of genes that were concordant, mixed (M1 and M2) or discordant for 
each drug pair. Genes that were unchanged in response to both drugs of a drug pair were removed from analysis.
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number suggesting antagonism between these two drugs at the 
concentrations used here. The combinations were ranked and 
then compared with the rankings of the drugs in terms of their 
transcriptional concordance, discordance, apoptosis response 
and cell cycle response (Fig. 4C). The best correlation occurred 
when MTT data was compared with overall gene concordance 
(Fig. 4D), suggesting that this was the best predictive measure 
for combinational efficiency.
Discussion
The current study compares the mRNA expression profiles of 
HCT116 tumour cells after they have been cultured with different 
chemotherapeutic agents. The tumour cells were cultured with 
suboptimal concentrations of different classes of chemotherapy 
and the response measured by whole‑genome microarray. 
Despite the different targets and mechanisms of action of the 
drugs, there were some similarities in the pattern of gene acti‑
vation/inhibition for some of the drugs. Moreover, drugs that 
displayed general concordance in gene signature were shown to 
exhibit synergistic traits when combined with one another.
A number of drugs have multiple mechanisms of action, and 
so deciding drug‑partners in combination regimens simply on 
the basis of the principal mechanism of action may inadvertently 
miss opportunities. For example, we have shown naltrexone, 
which is a proficient antagonist of opioid receptors can also 
reduce the expression of the cyclin‑dependent kinase inhibitor 
p21waf1 (22). This suggests it could be used in combination with 
other drugs that modify cell cycle functions. Previous studies 
have investigated the correlation between the mRNA expression 
patterns in tumour cells and; growth inhibition by agents (23), 
drug resistance (24,25) and prognosis (26), but these studies have 
usually focussed on untreated cells, and not attempted to predict 
combination value by comparing the mRNA expression profiles 
of tumour cells after culture with different classes of drug. In the 
current study, we specifically examined the gene signatures in 
one colon cancer cell line after treatment with a range of chemo‑
therapy drugs, and analysed these profiles for patterns that could 
identify similarities in MOAs. Data pertaining to certain genes 
from cells treated with gemcitabine has been published in our 
previous papers (5,7). Data pertaining to naltrexone has been 
published previously (30).
For some time now, the identification of genetic patterns 
in patients with certain types of cancer has been used as a 
prognostic indicator. Indeed, in some cases, establishing the 
genetic fingerprint of the a cancer can guide the type of treat‑
ment (27,28). The current study differs from this more general 
approach by first identifying the genes that are changed 
following treatment. It is hoped that by matching these 
signatures, certain drugs that have similar genetic profiles 
Figure 3. Apoptosis and cell cycle related genes were defined using Qiagen gene lists. Microarray data were then used to rank each gene in terms of its response 
to each drug. Graphs representing strongest and weakest correlations are presented. (A) There was a strong positive correlation between the way lenalidomide 
and docetaxel affected apoptosis genes. (B) There was no correlation between the way apoptosis genes were affected by naltrexone and oxaliplatin. (C) There 
was a strong positive correlation between the way lenalidomide and docetaxel affected cell cycle genes. (D) There was no correlation between the way 
apoptosis genes were affected by naltrexone and lenalidomide.
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may be supportive of one another. A similar study examining 
the RNAi signatures of mammalian cell death genes high‑
lighted the importance of mechanism in drug combination 
and revealed, for example, that the mapping of 17AAG and 
taxol in the same region in the principal component analysis 
space, supported the prediction that 17AAG would reinforce a 
taxol‑like action (29).
Our previous work has shown that the same agent can 
have diverse effects on genes when used at different concen‑
trations (30). At high concentrations, a number of drugs will 
cause a large amount of cell death and have a catastrophic 
effect on gene translation, so for this reason, we cultured cells 
with drugs at sub‑optimal concentrations. Additionally, micro‑
arrays were performed on RNA extracted from cells after 4 h 
of culture with drug to ensure that the secondary/tertiary 
effects of the drugs and non‑specific effects on gene expres‑
sion were minimised and so the primary fingerprint of effect 
could be determined for each drug. Artesunate, camptothecin, 
docetaxel, gemcitabine, lenalidomide, naltrexone and oxali‑
platin each initiated a particular gene response when cultured 
with HCT116 cells at suboptimal concentrations. However, 
despite the varying molecular targets and mechanisms of action 
for the drugs, there were similarities between the patterns of 
genes hits by certain pairs of drugs. For example, there was a 
remarkable concordance in the mRNA expression of tumour 
cells cultured with artesunate and lenalidomide. This despite 
the disparate nature of the mechanisms of action and molec‑
ular targets of these drugs, artesunate potentially working 
through iron‑catalysed alkylating cytotoxic free radicals in 
tumours and lenalidomide targeting cereblon (31). Conversely, 
drugs such as gemcitabine and docetaxel, and, naltrexone and 
camptothecin, had very different microarray responses, in 
many cases genes that were upregulated by one drug would be 
downregulated by the other. This kind of reciprocal response 
may be expected for drugs that, for example, target different 
points on the cell cycle, and although GO analysis (Table II) of 
the 50 most upregulated and the 50 most downregulated genes 
suggested that gemcitabine, although multifaceted, affects 
G2/M transition, while docetaxel affects cell division only, 
there were cell cycle protein‑specific changes that highlighted 
Table II. The one hundred most affected genes (by fold change) from microarray data for each drug were used as gene sets for 
analysis using the GO Resource Enrichment Analysis Tool. This analysis determines which GO terms are over‑ or under‑repre‑
sented using annotations for these gene sets. The table shows significant shared GO Biological Process terms used to describe 
each set of genes. These data reveal which cellular mechanisms may be hit by each drug. 
Drug GO Terms
Artesunate  Lipid droplet organization; intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; 
positive regulation of neuron apoptotic process; cellular protein localization; negative regulation of gene expres‑
sion; regulation of cellular metabolic process; regulation of primary metabolic process; regulation of nitrogen 
compound metabolic process.
Camptothecin  Positive regulation of extrinsic apoptotic signaling pathway via death domain receptors; intrinsic apoptotic 
signaling pathway in response to oxidative stress; DNA damage response, signal transduction by p53 class 
mediator resulting in cell cycle arrest; apoptotic mitochondrial changes; cellular response to UV; positive regula‑
tion of protein kinase B signalling; cellular response to starvation; positive regulation of protein kinase activity; 
regulation of cell population proliferation; regulation of response to stress.
Docetaxel Cell division.
Gemcitabine  Mitotic chromosome movement towards spindle pole; meiotic sister chromatid cohesion, centromeric; spindle 
assembly involved in meiosis; mitotic metaphase plate congression; mitotic spindle assembly checkpoint; DNA 
damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; cellular response to 
amino acid starvation; positive regulation of cyclin‑dependent protein kinase activity; regulation of cyclin‑depen‑
dent protein serine/threonine kinase activity; regulation of mitotic spindle organization; centromere complex 
assembly; mitotic spindle organization; regulation of cytokinesis; G2/M transition of mitotic cell cycle; cellular 
response to UV; anaphase‑promoting complex‑dependent catabolic process; cell division; intrinsic apoptotic 
signaling pathway; regulation of G2/M transition of mitotic cell cycle; positive regulation of cellular catabolic 
process; DNA conformation change; positive regulation of cell population proliferation; regulation of apoptotic 
process.
Lenalidomide N/A
Oxaliplatin  Response to corticosterone; DNA damage response, signal transduction by p53 class mediator resulting in cell 
cycle arrest; positive regulation of cysteine‑type endopeptidase activity involved in apoptotic process; intrinsic 
apoptotic signaling pathway; transcription initiation from RNA polymerase II promoter; cellular response to 
extracellular stimulus; regulation of neuron death; response to radiation; regulation of apoptotic signaling 
pathway; cell development; regulation of gene expression.
GO, gene ontology.
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this difference. For example, gemcitabine upregulated cyclin 
E and marginally downregulated cyclin A, while for docetaxel 
the opposite was true, cyclin E being reduced, and cyclin A 
being upregulated.
This kind of inverse response on gene transcription 
suggests that the drugs, when combined, would neutralise each 
other, abrogating the response of both in terms of gene changes 
and cytotoxicity/cytostasis. What may help to indicate an 
efficacious combination is by examining the effects of the 
drugs on genes regulating key processes such as apoptosis and 
the cell cycle. By focusing on apoptosis‑associated genes, it 
was revealed that docetaxel and lenalidomide had the most 
similar response i.e. both drugs showed a similar pattern of 
response in genes associated with apoptosis. This despite the 
fact that docetaxel is generally viewed as a potent cytotoxic 
agent, whilst lenalidomide is generally thought of as non‑toxic. 
Parallel to this, docetaxel and lenalidomide produced a similar 
response in cell cycle‑associated genes in HCT116 cells again 
signifying that although docetaxel and lenalidomide have 
different potencies and mechanisms of action, the end result of 
their use in HCT116 tumour cells is transcriptionally similar.
Cells contain numerous sensors that perceive damage and 
then relay this to machinery involved with cellular repair, 
death or senescence (32). The present study shows that even 
when using vastly differing chemotherapies with diverse 
molecular targets and MOAs, there can be an overlap in the 
mRNA‑transcripts that are affected. Moreover, correlation 
between chemotherapy and gene response cannot neces‑
sarily be predicted by the similarity of drugs. For example, 
gemcitabine and oxaliplatin both block DNA replication by 
inserting into DNA strands; however, in terms of the general 
mRNA response, only 4.2% of affected genes were ‘concor‑
dant’. Conversely, artesunate and oxaliplatin supposedly have 
totally different MOAs and yet 26.5% of genes were impacted 
by the individual drugs in the same way.
Upon determining the gene response to the various 
chemotherapies, we next wanted to know whether these could 
be predictive of the combination effect when using the drugs 
concomitantly. Intuitively, combining drugs with discordant 
gene signatures would lead to a situation where the effects 
imparted by the individual drugs would negate the actions 
of the other, thereby neutralising the response. However, 
combining drugs that were not discordant could potentially be 
beneficial as they could, for example, better activate desired 
gene responses in a cooperative manner (concordance) or 
activate more than one desired response (mixed). Indeed, 
using MTT analysis it was found that additivity between drugs 
correlated most strongly to overall gene concordance between 
drugs. That is to say, drugs with similarities in their tran‑
scriptional responses combined better to reduce cell number, 
compared to those with transcriptional effects that were less 
similar.
Figure 4. Combination effectiveness was determined by a MTT assay correlated with gene expression concordance. (A) Representative MTT experiment 
demonstrating raw absorbance data from a single MTT assay corresponding to the number of metabolically viable HCT116 cells after various treatments and 
combinations. (B) The efficiency of each drug combination. Each drug combination is presented on the x‑axis while columns represent percentage difference 
from the expected cell number reduction if the drug combinations were additive. Combinations where the percentage difference was positive or negative 
exhibit a detrimental or beneficial effect of the combination on cell number. Data are presented as the mean difference from three separate experiments. 
(C) Chemotherapy combinations were ranked in terms of their ability to reduce cell number better than expected. These rankings were then correlated with 
those for gene concordance, discordance, apoptosis gene response and cell cycle gene response using Spearman's rank correlation. (D) The combination 
efficiency of two drugs, as defined as a better than expected result from MTT assays, most strongly correlated with gene concordance between the two drugs.
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The fundamental rationale for combination therapy in an 
oncology setting is to optimise overall action by using drugs 
that work together to target tumour masses that contain cells 
that are often heterogeneous (33). This heterogeneity means 
that the cell types can be diverse enough to prevent drugs with 
focussed MOAs lacking the activity to elicit a therapeutic 
effect. Therefore, mixing drugs to allow a more diverse range 
of action could be beneficial. Similarly, it could be argued that 
the over‑reliance of a drug concentrating on one specific target 
could allow resistance to the drug to develop more readily (34). 
However, even drugs with very similar MOAs can have very 
different responses, such as those reported with platinum 
derivatives in cisplatin‑resistant cell lines (35). Despite this, 
most clinical data and scientific dogma would suggest that 
combining drugs with identical MOAs would not be best 
practise and this idea is still maintained in the present study, 
which suggests not combining similar drugs but combining 
very different drugs that have a similarity of response at the 
transcriptional level. Further investigation of this effect using 
more cell lines and different chemotherapies is needed to 
determine whether this theory holds true.
Due to the nature of the study the combination that performed 
best in terms of reduction of cell number may not have been the 
combination that reduced cell number to the largest extent, as 
combinations were ranked in terms of performance compared 
to predicted performance, not which combination reduced cell 
number the most. This study is also limited by the fact that only 
one concentration of each of the drugs was used. We can say with 
some certainty that titration of the drugs to different concentra‑
tions will produce a different pattern of transcriptional response 
and it may also be that changing the concentrations will also 
influence whether the drug combinations retain their beneficial or 
detrimental effects on tumour cell number. A further confounding 
factor not even touched upon in this study is the importance of 
drug sequence when using more than one agent (22,36). For these 
reasons, these data can only be used as a guide as to which drugs 
may combine well with one another and it is essential that further 
studies include an investigation of drug dose.
The present study suggests that an important factor in the 
strategic combination of chemotherapies may be that there is 
some correlation in the transcriptional response induced by 
the chemotherapeutics that are being combined. That is not 
to say that the drugs should not have different targets and 
mechanisms but the present data suggest that the outcome of 
this should be a similar pattern of gene expression to allow the 
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